製品名:4-Bromo-2-fluorotoluene

IUPAC Name:4-bromo-2-fluoro-1-methylbenzene

CAS番号:51436-99-8
分子式:C7H6BrF
純度:95%+
カタログ番号:CM253316
分子量:189.03

包装単位 有効在庫 価格(USD) 数量
CM253316-1000g in stock Ʃœȋ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:51436-99-8
分子式:C7H6BrF
融点:-
SMILESコード:C1=C(C(=CC=C1Br)C)F
密度:
カタログ番号:CM253316
分子量:189.03
沸点:183.2°C at 760 mmHg
MDL番号:MFCD00013551
保管方法:Store at room temperature.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Crinecerfont
The New England Journal of Medicine publishes the primary CAHtalyst™ Adult Phase 3 study results of Crinecerfont for the treatment of congenital adrenal hyperplasia (CAH). Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare genetic disorder, affected by a lack of cortisol and/or aldosterone. Corticotropin-releasing factor type 1 receptor (CRF1) antagonism is shown to clinically decrease ACTH production and adrenal androgen levels.
Neurocrine's Crinecerfont is an investigational, selective CRF1 antagonist being developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens. The phase 3 study meets primary and important key secondary endpoints, including a significant reduction in androstenedione levels and lowering glucocorticoid dosing.